Biology:MDA-MB231

From HandWiki

MDA-MB-231 (M D Anderson - Metastatic Breast - 231) is a human breast cancer cell line isolated at MD Anderson Cancer Center in 1973 that is used in therapeutic research, especially in the context of triple negative breast cancer.[1][2]

History and characteristics

MDA-MB-231 cells were derived from a pleural effusion due to an adenocarcinoma originating in a 51-year-old caucasian female.[2] The cell line is triple negative, meaning it lacks oestrogen receptors, progesterone receptors, and HER2 (human epidermal growth factor receptor 2) amplification which many current treatment options rely on making it difficult to cure.[3][4] In addition, this cell line has a low expression of the Ki-67 proliferation marker, down regulation of claudin-3 and claudin-4, enrichment for markers associated with the epithelial-mesenchymal transition and the CD44+CD24-/low phenotype associated with breast cancer stem cells and increased metastasis,[5][6][7] and is a mutant in the p53 and KRas oncogenes.[8][9] The cells are considered biosafety level 1. They can be grown in 2 or 3-D cultures.[10]

Research applications

MDA-MB-231 is used to study potential treatments for a cancer with currently limited treatment options by either improving current medication delivery and efficacy,[11][12] or by trying new treatment courses.[13][14]

This cell line has also been utilized to study metastasis to the bones[15][16] and lungs.[16][17]

See also

References

  1. ↑ "Breast tumor cell lines from pleural effusions". Journal of the National Cancer Institute 53 (3): 661–674. September 1974. doi:10.1093/jnci/53.3.661. PMID 4412247. 
  2. ↑ 2.0 2.1 "Cellosaurus MDA-MB-231 (CVCL_0062)". January 30, 2024. https://www.cellosaurus.org/CVCL_0062. 
  3. ↑ "PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro". Breast Cancer Research and Treatment 79 (1): 63–74. May 2003. doi:10.1023/a:1023366117157. PMID 12779083. 
  4. ↑ "Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer". Breast Disease 32 (1–2): 35–48. 2010. doi:10.3233/BD-2010-0307. PMID 21778573. 
  5. ↑ "Choosing the right cell line for breast cancer research". Breast Cancer Research 13 (4): 215. August 2011. doi:10.1186/bcr2889. PMID 21884641. 
  6. ↑ "Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer". Breast Cancer Research 12 (5): R68. 2010. doi:10.1186/bcr2635. PMID 20813035. 
  7. ↑ "Role of Claudin Proteins in Regulating Cancer Stem Cells and Chemoresistance-Potential Implication in Disease Prognosis and Therapy". International Journal of Molecular Sciences 21 (1): 53. December 2019. doi:10.3390/ijms21010053. PMID 31861759. 
  8. ↑ "Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines". Breast Cancer Research and Treatment 121 (1): 53–64. May 2010. doi:10.1007/s10549-009-0460-8. PMID 19593635. https://hal.archives-ouvertes.fr/hal-00485063/file/PEER_stage2_10.1007%252Fs10549-009-0460-8.pdf. 
  9. ↑ "Activation of KRAS promotes the mesenchymal features of basal-type breast cancer". Experimental & Molecular Medicine 47 (1): e137. January 2015. doi:10.1038/emm.2014.99. PMID 25633745. 
  10. ↑ "Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model". OncoTargets and Therapy 13: 5395–5405. 2020-06-11. doi:10.2147/OTT.S249756. PMID 32606757. 
  11. ↑ "Effects of curcumin complexes on MDA‑MB‑231 breast cancer cell proliferation". International Journal of Oncology 57 (2): 445–455. August 2020. doi:10.3892/ijo.2020.5065. PMID 32626932. 
  12. ↑ "Efficient delivery of methotrexate to MDA-MB-231 breast cancer cells by a pH-responsive ZnO nanocarrier". Scientific Reports 13 (1): 21899. December 2023. doi:10.1038/s41598-023-49464-9. PMID 38081993. Bibcode: 2023NatSR..1321899R. 
  13. ↑ "Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin β3". Biomedical Journal 44 (6 Suppl 1): S84–S92. December 2021. doi:10.1016/j.bj.2020.07.004. PMID 35652598. 
  14. ↑ "Synthesis of potent MDA-MB 231 breast cancer drug molecules from single step". Scientific Reports 13 (1): 18241. October 2023. doi:10.1038/s41598-023-45455-y. PMID 37880270. Bibcode: 2023NatSR..1318241G. 
  15. ↑ "Murine models of breast cancer bone metastasis". BoneKEy Reports 5: 804. 2016. doi:10.1038/bonekey.2016.31. PMID 27867497. 
  16. ↑ 16.0 16.1 "Breast cancer cells that preferentially metastasize to lung or bone are more glycolytic, synthesize serine at greater rates, and consume less ATP and NADPH than parent MDA-MB-231 cells". Cancer & Metabolism 11 (1): 4. February 2023. doi:10.1186/s40170-023-00303-5. PMID 36805760. 
  17. ↑ "Genes that mediate breast cancer metastasis to lung". Nature 436 (7050): 518–524. July 2005. doi:10.1038/nature03799. PMID 16049480. Bibcode: 2005Natur.436..518M. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:MDA-MB231&oldid=4331153"